Pfizer paid $330 million upfront for three Starna in vivo CAR-T programs in autoimmune disease, plus up to $2.3 billion in milestones. What it means.
Last updated: November 20, 2026
Pfizer licensed three early in vivo CAR-T programs for autoimmune disease from Starna Therapeutics on November 18, 2026, paying $330 million upfront with up to $2.3 billion in milestones plus royalties. It gets rights outside Greater China, an option on China, and plans to make early trial supply in the United States.
Scope: the Pfizer and Starna deal terms from Pfizer’s release, the in vivo CAR-T race, and how the deal fits the policy fight over China licensing that a congressional commission escalated the same day.
What did Pfizer buy from Starna?
Pfizer bought exclusive rights outside Greater China to three in vivo chimeric antigen receptor T cell (CAR-T) programs aimed at autoimmune diseases, all still before an investigational new drug filing. The deal was announced in a Business Wire release dated Wednesday, November 18, 2026, 6:45 am ET.
The package is wider than three molecules. According to Pfizer’s release, Pfizer also gets rights to use Starna’s in vivo CAR-T technology in inflammation and immunology and in oncology, options to exclusively license compounds coming out of a separate research collaboration, and an option to expand its territory to include Greater China.
Starna describes itself as a company developing RNA medicines designed to enable in vivo therapeutics. CEO Rongkuan Hu, Ph.D., pointed to Starna’s “proprietary targeted LNP delivery platform and RNA technology” as the foundation for the programs. The release does not name the CAR targets.
How much is the Pfizer Starna deal worth?
The deal is worth up to about $2.63 billion before royalties: $330 million upfront plus up to $2.3 billion in development and commercial milestones. That total is our arithmetic from the two figures in Pfizer’s release, and royalty rates were not disclosed.
| Term | What Pfizer’s release says |
|---|---|
| Upfront payment | $330 million to Starna |
| Milestones | Up to $2.3 billion, development and commercial |
| Royalties | On net sales of approved products; rates not disclosed |
| Programs | Three in vivo CAR-T programs, autoimmune disease, before IND |
| Territory | Outside Greater China, with an option to add Greater China |
| Platform rights | Starna technology in inflammation and immunology and oncology; options on compounds from a separate research collaboration |
| Development | Pfizer leads clinical development outside Greater China |
| Manufacturing | Pfizer plans to make finished drug product for initial trials at its US facilities |
| Commercialization | Pfizer has sole and exclusive control outside Greater China |
| Not disclosed | CAR targets, royalty rates, China option price, closing conditions, timing |
Read the shape, not just the size. The upfront is roughly one eighth of the headline total (our arithmetic), which is a real check for programs that have not reached a US IND. The rest depends on clinical and commercial events that sit years out.
What is in vivo CAR-T and why does pharma want it?
In vivo CAR-T aims to create CAR T cells inside the patient’s body instead of collecting a patient’s T cells, engineering them in a factory and infusing them back. Starna’s approach, per its CEO, uses targeted lipid nanoparticles to deliver RNA.
The appeal is operational. Today’s approved CAR-T products are personalized and made one patient at a time, which limits capacity and pushes cost up. An off the shelf product shipped like a drug would change the math for autoimmune diseases, where patient numbers are far larger than in blood cancers. Pfizer’s own framing was clinical: Michael Vincent, M.D., Ph.D., Pfizer’s Chief Inflammation and Immunology Officer, said “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases.”
The release also leans on Pfizer’s RNA background. Vincent also pointed to Pfizer’s significant experience developing and manufacturing RNA based medicines globally. That is the strategic logic here: an LNP and RNA platform plays to a manufacturing base Pfizer already runs.
Who else is racing in in vivo CAR-T?
Pfizer is late to the field and is paying to catch up. BioPharma Dive, which called this Pfizer’s first venture into this area of research, listed acquisitions centered on the technology by AstraZeneca (EsoBiotec), AbbVie (Capstan), Gilead Sciences (Interius) and Bristol Myers Squibb (Orbital). It did not give values for those deals in its article.
Johnson and Johnson took an option route in July 2026. BioXconomy reported J&J committed $785 million in total upfront payments to Sail Biomedicines, including a $465 million equity investment, with an option that would take the full price to $2.58 billion if exercised. Those figures are attributed to BioXconomy; we did not fetch the J&J release.
The other side of the ledger is safety. BioPharma Dive reported that Novartis and Bristol Myers both recently paused trials of CAR-T therapies in autoimmune conditions because of safety concerns. Autoimmune patients are not cancer patients, and the tolerance for serious toxicity is much lower. Every in vivo program will be judged against that bar.
Why did Pfizer license instead of buying Starna?
The structure fits both the asset’s stage and the policy climate. A license with options keeps Pfizer’s cash at risk small relative to the headline, and it stays clear of acquiring a platform company outright, which is exactly where China and Washington are both tightening.
China proposed export restrictions in October 2026 on certain next generation biopharma technologies, including proprietary drug discovery platforms, while exempting specified licensing agreements, according to the report released by the National Security Commission on Emerging Biotechnology (NSCEB). The commission notes those rules are not yet final. We covered the draft when it surfaced; Fierce Biotech reported at the time that it would bar foreign acquisition of cell and gene therapy and siRNA platforms while leaving out licensing alone.
Our read: Pfizer took the lane both capitals still leave open. It rents the output, keeps an option on China, and moves early manufacturing onshore. That last point matters in a year when sponsors are rebuilding supply chains around BIOSECURE and the Pentagon’s 1260H list.
What did the congressional commission say about China licensing?
On the same day as the Pfizer deal, the NSCEB published “Made Innovated in China,” a report arguing the PRC is progressing toward capturing the US pharmaceutical market. It analyzed 57 deals between the top 15 pharmaceutical companies by revenue operating in the United States and 42 Chinese biotechnology companies from January 2023 to October 2026.
The commission found upfront values are rising and are increasingly based on preclinical data. It described deal structures escalating from single asset out licensing to multi asset deals to discovery platform co development, flagged the NewCo model as redirecting US capital away from US innovation, and called the Treasury’s proposed prohibitions on outbound US investment in Chinese biotech “a prudent step.” It also cites a September 2026 Chinese pharma plan that aims to dramatically increase first in class drug output by 2030.
The Pfizer deal reads like a case study for that report: preclinical assets, a large upfront, platform rights and options. The report does not mention Starna.
What should biopharma teams take from the deal? (Our framework)
This is our checklist for business development, manufacturing and policy teams weighing a China sourced in vivo cell therapy license.
- Separate molecule rights from platform rights. Pfizer got both. Know which one carries the value and which one draws scrutiny.
- Price the China option now. An undisclosed option price is a future negotiation, not a free right.
- Plan onshore supply early. Pfizer committed to US made trial supply from the start. Map where LNP, RNA and fill finish steps sit before IND.
- Underwrite safety for autoimmune use. Peer pauses show the bar. Build stopping rules and monitoring into the first protocol.
- Model the policy path. Track China’s final export rules, Treasury’s outbound investment rule and any congressional follow up to the NSCEB report.
- Check milestone timing against cash. With programs before IND, most of the $2.3 billion is years away and conditional.
What to watch next
- Pfizer naming CAR targets and first indications, and an IND filing timeline.
- Whether Pfizer exercises the Greater China option and on what terms.
- China’s final export control catalogue and whether licensing stays exempt.
- Treasury’s outbound investment rule on Chinese biotech and any legislative action after the NSCEB report.
- Clinical safety updates from in vivo CAR-T programs in autoimmune disease across the field.
FAQ
What did Pfizer announce with Starna Therapeutics?
On November 18, 2026, Pfizer announced an exclusive license to three in vivo CAR-T programs for autoimmune diseases from Starna Therapeutics, with rights outside Greater China and an option to add Greater China.
How much is Pfizer paying Starna upfront?
Pfizer is paying Starna $330 million upfront, according to Pfizer’s release.
What is the total potential value of the Pfizer Starna deal?
Up to about $2.63 billion before royalties, combining the $330 million upfront and up to $2.3 billion in milestones. The total is our arithmetic; royalties come on top.
What stage are the Starna programs?
All three are before an investigational new drug filing, meaning no US investigational new drug application has been filed for them yet.
What technology does Starna use?
Starna’s CEO described a proprietary targeted lipid nanoparticle delivery platform and RNA technology to generate CAR T cells inside the body.
Does Pfizer get rights in China?
Not yet. Pfizer’s rights cover territories outside Greater China, and it holds an option to expand to Greater China. The option price was not disclosed.
Where will Pfizer manufacture the drug?
Pfizer plans to manufacture finished drug product for the initial clinical trials at its US facilities, per the release.
Which other companies are working on in vivo CAR-T?
BioPharma Dive listed AstraZeneca, AbbVie, Gilead and Bristol Myers Squibb as having acquired in vivo technology companies, and J&J holds an option to buy Sail Biomedicines, per BioXconomy.
What is the NSCEB report?
“Made Innovated in China” is a November 2026 report from the National Security Commission on Emerging Biotechnology warning that China is advancing toward capturing the US pharmaceutical market through licensing and other deals.
Is the Pfizer Starna deal closed?
Pfizer’s release did not state closing conditions or timing, so we cannot confirm the status of any regulatory clearances.
Sources
- Pfizer, “Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases,” Business Wire, Nov 18, 2026 (primary): pfizer.com
- National Security Commission on Emerging Biotechnology, “Made Innovated in China,” November 2026 (primary for the commission’s findings): biotech.senate.gov
- BioPharma Dive, Kristin Jensen, Nov 18, 2026 (attributed: peer in vivo acquisitions, Novartis and BMS trial pauses): biopharmadive.com
- BioXconomy, July 31, 2026 (attributed: J&J and Sail terms): bioxconomy.com
- PharmExec, Nov 18, 2026 (corroboration of Pfizer terms): pharmexec.com
Related coverage
- Roche pays Hansoh $400 million upfront in an ADC platform pact
- WuXi AppTec delisted from the 1260H list: what it means for sponsors
- Earnouts, CVRs and royalties: how biotech deals bridge value gaps
- CorMedix to buy Heron’s assets in a $222.6 million upfront deal
- Biosimilar patent dance: why FDA approval does not mean launch
- BioMed Nexus company directory
Get the daily briefing on biotech, pharma and medtech: subscribe to BioMed Nexus.


